RT Journal Article
SR Electronic
T1 The economic burden of metastatic breast cancer in Spain
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP 19
OP 24
DO 10.1136/ejhpharm-2017-001453
VO 27
IS 1
A1 Begoña Bermejo de las Heras
A1 Javier Cortes Ramon y Cajal
A1 Elena Galve Calvo
A1 Juan de la Haba Rodriguez
A1 Jesus Garcia Mata
A1 Fernando Moreno Anton
A1 Ignacio Pelaez Fernandez
A1 Alvaro Rodriguez-Lescure
A1 Cesar A Rodriguez Sanchez
A1 Manuel Ruiz-Borrego
A1 Edit Remak
A1 Magdolna Barra
A1 Maria Rivero
A1 Javier Soto Alvarez
YR 2020
UL http://ejhp.bmj.com/content/27/1/19.abstract
AB Objectives The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years.Methods An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles.Results The incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2−/HR+, 520 HER2+/HR+, 324 HER2+/HR−, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2−/HR+, 2.82 years for HER2+/HR− and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR−and €94,572 for triple negative patients over 5 years.Conclusions The economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2−/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.